Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 33 min ago
PreprintCC BY-NC-NDmedRxiv

Blood-based PhenoAge may reflect disease burden rather than biological aging in cancer

  • A. K. Simhal1
  • J. Lee
  • K. S. Tan
  • P. J. McCormick
  • G. W. Fischer
  • J. R. Scarpa
  • G. Sapiro
  • J. S. Mincer
  1. 1Memorial Sloan Kettering Cancer Center
Read full textPDFDOICite

Abstract

PhenoAge, a blood-based biological aging clock, is associated with cancer outcomes, a finding taken as evidence that biological aging shapes prognosis. In 3,067 patients undergoing primary tumor resection, PhenoAge acceleration rose with tumor stage. One or two of its eight blood components, differing by cancer type, carried the prognostic signal, and replacing its general-population weights with equal weights did not weaken it. In cancer, PhenoAge may reflect disease burden rather than biological aging.

Related

  1. Parental Dementia History is Associated with Peripheral Immune Aging Rather than Generalized Biological and Brain Age Acceleration in Midlife
    Edric D. Winford, Benjamin D. Huber, Justina F. Avila-Rieger +7
    medRxivPreprintAll rights reservedFull textEpidemiology & public healthmedRxivPMC
  2. Age-related alterations in blood fatty acid composition and ratios, omega-3 fatty acid levels and association with PhenoAge acceleration: a cross-sectional analysis of the NHANES 2021-2023 data
    A. Pietzner, N. Rohwer, K. H. Weylandt
    medRxivPreprintAll rights reservedFull textNutritionmedRxiv
  3. Circulating biomarkers reflect distinct quantitative CT-defined features of systemic sclerosis-associated interstitial lung disease
    Fabrizio Conti, Valeria Riccieri, Greta Pellegrino +14
    RMD OpenPeer-reviewedCC BYFull textGeneral medicineDOAJ
  4. Beyond mutation burden: biological termination as a systems perspective on cancer.
    Ivan Shterev Donev, Mila Petrova Petrova, Mariyana Ilieva Eneva +2
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textOncologyEurope PMCPMC
  5. Multicenter development and validation of a serum microRNA-based diagnostic model for breast cancer and its association with tumor burden and biological aggressiveness: an observational case-control study.
    Ayane Yamaguchi, Kana Kawanishi, Kei Ishii +16
    Breast cancer research : BCRPeer-reviewedCC BYFull textOncologyEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@misc{simhal2026bloodbased,
  title = {{Blood-based PhenoAge may reflect disease burden rather than biological aging in cancer}},
  author = {A. K. Simhal and J. Lee and K. S. Tan and P. J. McCormick and G. W. Fischer and J. R. Scarpa and G. Sapiro and J. S. Mincer},
  howpublished = {medRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.15.26365671},
  url = {https://www.medrxiv.org/content/10.64898/2026.10.15.26365671v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - Blood-based PhenoAge may reflect disease burden rather than biological aging in cancer
AU  - A. K. Simhal
AU  - J. Lee
AU  - K. S. Tan
AU  - P. J. McCormick
AU  - G. W. Fischer
AU  - J. R. Scarpa
AU  - G. Sapiro
AU  - J. S. Mincer
PY  - 2026
DA  - 2026/10/15
PB  - medRxiv
DO  - 10.64898/2026.10.15.26365671
UR  - https://www.medrxiv.org/content/10.64898/2026.10.15.26365671v1
AB  - PhenoAge, a blood-based biological aging clock, is associated with cancer outcomes, a finding taken as evidence that biological aging shapes prognosis. In 3,067 patients undergoing primary tumor resection, PhenoAge acceleration rose with tumor stage. One or two of its eight blood components, differing by cancer type, carried the prognostic signal, and replacing its general-population weights with equal weights did not weaken it. In cancer, PhenoAge may reflect disease burden rather than biological aging.
ER  -